Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Open access
Pearson, Alex, Smyth, Elizabeth, Babina, Irina S., Herrera-Abreu, Maria Teresa, Tarazona, Noelia, Peckitt, Clare, Kilgour, Elaine, Smith, Neil R., Geh, Catherine, Rooney, Claire, Cutts, Ros, Campbell, James, Ning, Jian, Fenwick, Kerry, Swain, Amanda, Brown, Gina, Chua, Sue, Thomas, Anne, Johnston, Stephen R.D., Ajaz, Mazhar, Sumpter, Katherine, Gillbanks, Angela, Watkins, David, Chau, Ian, Popat, Sanjay, Cunningham, David, Turner, Nicholas C.·2016·Cancer Discovery

Abstract

FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level clonal FGFR2 amplification have a high response rate to the selective FGFR inhibitor AZD4547, whereas cancers with subclonal or low-level amplification did not respond. Using cell lines and patient-derived xenograft models, we show that high-level FGFR2 amplification initiates a distinct oncogene addiction phenotype, characterized by FGFR2-mediated transactivation of alternative receptor kinases, bringing PI3K/mTOR signaling under FGFR control. Signaling in low-level FGFR1-amplified cancers is more restricted to MAPK signaling, limiting sensitivity to FGFR inhibition. Finally, we show that circulating tumor DNA screening can identify high-level clonally amplified cancers. Our data provide a mechanistic understanding of the distinct pattern of oncogene addiction seen in highly amplified cancers and demonstrate the importance of clonality in predicting response to targeted therapy. Significance: Robust single-agent response to FGFR inhibition is seen only in high-level FGFR-amplified cancers, with copy-number level dictating response to FGFR inhibition in vitro, in vivo, and in the clinic. High-level amplification of FGFR2 is relatively rare in gastric and breast cancers, and we show that screening for amplification in circulating tumor DNA may present a viable strategy to screen patients. Cancer Discov; 6(8); 838–51. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 803

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-1246

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 276

Metadata

Authors
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., Cutts, R., Campbell, J., Ning, J., Fenwick, K., Swain, A., Brown, G., Chua, S., Thomas, A., Johnston, S. R. D., Ajaz, M., Sumpter, K., Gillbanks, A., Watkins, D., Chau, I., Popat, S., Cunningham, D., & Turner, N. C.
Venue
Cancer Discovery
Published
2016-08-01
Volume
6
Issue
8
Pages
838-851
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2368819226
Cited by
276
References
23
FWCI
17.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. https://app.cochat.ai/papers/10.1158/2159-8290.cd-15-1246
The paper
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., Cutts, R., Campbell, J., Ning, J., Fenwick, K., Swain, A., Brown, G., Chua, S., Thomas, A., Johnston, S. R. D., . . . Turner, N. C. (2016). High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-15-1246

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.